董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Omid Farokhzad | 男 | Chief Executive Officer and Chair of the Board of Director | 51 | 75.11万美元 | 未持股 | 2020-11-06 |
| Terrance McGuire | 男 | Director | 64 | 未披露 | 未持股 | 2020-11-06 |
| Omead Ostadan | 男 | President, Chief Operating Officer and Director | 48 | 未披露 | 未持股 | 2020-11-06 |
| Catherine J. Friedman | 女 | Director | 60 | 未披露 | 未持股 | 2020-11-06 |
| David Singer | 男 | Director | 58 | 未披露 | 未持股 | 2020-11-06 |
| David Hallal | 男 | Lead Independent Director | 54 | 未披露 | 未持股 | 2020-11-06 |
| Robert Langer | 男 | Director | 72 | 未披露 | 未持股 | 2020-11-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Omid Farokhzad | 男 | Chief Executive Officer and Chair of the Board of Director | 51 | 75.11万美元 | 未持股 | 2020-11-06 |
| Elona Kogan | 女 | General Counsel and Secretary | 51 | 未披露 | 未持股 | 2020-11-06 |
| David R. Horn | 男 | Chief Financial Officer | 53 | 未披露 | 未持股 | 2020-11-06 |
| Omead Ostadan | 男 | President, Chief Operating Officer and Director | 48 | 未披露 | 未持股 | 2020-11-06 |
| Elona Kogan | 女 | General Counsel and Secretary | 51 | 未披露 | 未持股 | 2020-11-06 |
董事简历
中英对照 | 中文 | 英文- Omid Farokhzad
-
Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
Omid Farokhzad,has served as a member of Senti Biosciences, Inc. board of directors since the closing of Senti Biosciences, Inc. Business Combination in June 2022. He founded Seer, Inc. (Nasdaq: SEER) in 2017, which advances a transformative proteomics platform, and has served as its Chief Executive Officer since February 2018 and as a member of its board of directors since March 2017, serving as the Chair since September 2020. He also served as Founder, Chief Executive Officer and Chair of Senti Biosciences, Inc. predecessor, Dynamics Special Purpose Corp. (NASDAQ: DYNS) from March 2021 to June 2022. He previously co-founded BIND Therapeutics (acquired by Pfizer Inc. (NYSE: PFE)), Selecta Biosciences, Inc. (Nasdaq: SELB), which is developing a novel antigen-specific tolerance platform for biologics and gene therapy, and Tarveda Therapeutics, Inc., a privately held oncology biotherapeutics company. From September 2004 to February 2018, he was a Professor at Harvard Medical School and a director of the Center for Nanomedicine at Brigham and Women's Hospital. Dr. Farokhzad holds an MA and M.D. from Boston University and an MBA from MIT Sloan School of Management. - Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
- Omid Farokhzad,has served as a member of Senti Biosciences, Inc. board of directors since the closing of Senti Biosciences, Inc. Business Combination in June 2022. He founded Seer, Inc. (Nasdaq: SEER) in 2017, which advances a transformative proteomics platform, and has served as its Chief Executive Officer since February 2018 and as a member of its board of directors since March 2017, serving as the Chair since September 2020. He also served as Founder, Chief Executive Officer and Chair of Senti Biosciences, Inc. predecessor, Dynamics Special Purpose Corp. (NASDAQ: DYNS) from March 2021 to June 2022. He previously co-founded BIND Therapeutics (acquired by Pfizer Inc. (NYSE: PFE)), Selecta Biosciences, Inc. (Nasdaq: SELB), which is developing a novel antigen-specific tolerance platform for biologics and gene therapy, and Tarveda Therapeutics, Inc., a privately held oncology biotherapeutics company. From September 2004 to February 2018, he was a Professor at Harvard Medical School and a director of the Center for Nanomedicine at Brigham and Women's Hospital. Dr. Farokhzad holds an MA and M.D. from Boston University and an MBA from MIT Sloan School of Management.
- Terrance McGuire
-
Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Terrance McGuire has served as a member of our board of directors since December 2017. Mr. McGuire serves as a General Partner of Polaris Partners, a venture capital firm he co-founded in 1996. He currently serves on the board of directors of Alector, Inc. and Cyclerion, Inc., and previously served on the board of directors of Acceleron Pharma, Inc., Arsanis, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire also serves as a member of the board of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, The Arthur Rock Center for Entrepreneurship at Harvard Business School and The Healthcare Initiative Advisory Board and on the Board of Advisors of the Thayer School of Engineering at Dartmouth College. Mr. McGuire holds a B.S. in Physics and Economics from Hobart College, an M.S. in Engineering from the Thayer School at Dartmouth College and an M.B.A. from Harvard Business School. - Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Terrance McGuire has served as a member of our board of directors since December 2017. Mr. McGuire serves as a General Partner of Polaris Partners, a venture capital firm he co-founded in 1996. He currently serves on the board of directors of Alector, Inc. and Cyclerion, Inc., and previously served on the board of directors of Acceleron Pharma, Inc., Arsanis, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire also serves as a member of the board of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, The Arthur Rock Center for Entrepreneurship at Harvard Business School and The Healthcare Initiative Advisory Board and on the Board of Advisors of the Thayer School of Engineering at Dartmouth College. Mr. McGuire holds a B.S. in Physics and Economics from Hobart College, an M.S. in Engineering from the Thayer School at Dartmouth College and an M.B.A. from Harvard Business School.
- Omead Ostadan
-
Omead Ostadan自2020年7月起担任Seer，Inc.的总裁兼首席运营官，并自2020年3月起成为Seer，Inc.的董事会成员。在加入Seer，Inc.之前，Ostadan先生于2007年1月至2020年6月在生物技术公司Illumina，Inc.任职，担任各种执行职务，最近于2019年7月至2020年6月担任高级副总裁兼首席产品和营销官，2015年4月至2019年6月任产品和营销高级副总裁。奥斯塔丹先生拥有加利福尼亚大学戴维斯分校生物化学理学学士学位和沃顿商学院工商管理硕士学位。
Omead Ostadan has served as Seer, Inc.'s President and Chief Operating Officer since July 2020 and as a member of Seer, Inc.'s board of directors since March 2020. Prior to joining Seer, Inc., Mr. Ostadan was with Illumina, Inc., a biotechnology company, from January 2007 to June 2020 where he served in various executive roles, most recently as Senior Vice President & Chief Products and Marketing Officer from July 2019 to June 2020 and Senior Vice President, Products & Marketing from April 2015 to June 2019. Mr. Ostadan holds a B.Sc in Biochemistry from the University of California, Davis and an M.B.A from the Wharton School of Business. - Omead Ostadan自2020年7月起担任Seer，Inc.的总裁兼首席运营官，并自2020年3月起成为Seer，Inc.的董事会成员。在加入Seer，Inc.之前，Ostadan先生于2007年1月至2020年6月在生物技术公司Illumina，Inc.任职，担任各种执行职务，最近于2019年7月至2020年6月担任高级副总裁兼首席产品和营销官，2015年4月至2019年6月任产品和营销高级副总裁。奥斯塔丹先生拥有加利福尼亚大学戴维斯分校生物化学理学学士学位和沃顿商学院工商管理硕士学位。
- Omead Ostadan has served as Seer, Inc.'s President and Chief Operating Officer since July 2020 and as a member of Seer, Inc.'s board of directors since March 2020. Prior to joining Seer, Inc., Mr. Ostadan was with Illumina, Inc., a biotechnology company, from January 2007 to June 2020 where he served in various executive roles, most recently as Senior Vice President & Chief Products and Marketing Officer from July 2019 to June 2020 and Senior Vice President, Products & Marketing from April 2015 to June 2019. Mr. Ostadan holds a B.Sc in Biochemistry from the University of California, Davis and an M.B.A from the Wharton School of Business.
- Catherine J. Friedman
-
Catherine J. Friedman，自2013年以来我们的董事会成员。她自2006年起成为一名公共和私人增长公司的独立咨询师。在此之前，她从1997年到2006年担任摩根士丹利的董事总经理；从1993年到2006年任西海岸医疗和生物技术实践的负责人及摩根士丹利（Morgan Stanley）的联席董事。自2007年以来，她曾在一个公开上市的生物制药公司XenoPort 公司的董事会任职，也在其审计和治理委员会任职。她于2007年加入一家公开上市的医疗器械公司Enteromedics的董事会，也担任其审计委员会的主席。她是半岛酒店的the Boys and Girls Club的董事会成员达七年之久，在那里她是行政和程序委员会的成员。她是阿瑟顿圣心学校董事会的成员。她有哈佛大学学士学位，获得了弗吉尼亚大学达顿商学院的MBA学位。
Catherine J. Friedman has served as a member of our board of directors since September 2020. Ms. Friedman has been an independent financial consultant serving public and private companies in the life sciences industry since 2006. Ms. Friedman served in various executive roles from 1982 to 2006 at Morgan Stanley, an investment bank and financial services company, including as Manager Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. She currently serves as Chairperson of the board at GRAIL, Inc., a cancer testing company, and on the board of directors of Altaba Inc., a closed-end management investment company formerly Yahoo! Inc., and Radius Health, Inc., a biopharmaceutical company. Ms. Friedman previously served on the board of directors of EnteroMedics, Inc., GSV Capital Corp., Innoviva, Inc. (formerly Theravance, Inc.), and XenoPort, Inc. She holds an A.B. in Economics from Harvard University and an M.B.A. from the University of Virginia Darden School of Business, where she serves as a member of the Darden School Foundation Board of Trustees. - Catherine J. Friedman，自2013年以来我们的董事会成员。她自2006年起成为一名公共和私人增长公司的独立咨询师。在此之前，她从1997年到2006年担任摩根士丹利的董事总经理；从1993年到2006年任西海岸医疗和生物技术实践的负责人及摩根士丹利（Morgan Stanley）的联席董事。自2007年以来，她曾在一个公开上市的生物制药公司XenoPort 公司的董事会任职，也在其审计和治理委员会任职。她于2007年加入一家公开上市的医疗器械公司Enteromedics的董事会，也担任其审计委员会的主席。她是半岛酒店的the Boys and Girls Club的董事会成员达七年之久，在那里她是行政和程序委员会的成员。她是阿瑟顿圣心学校董事会的成员。她有哈佛大学学士学位，获得了弗吉尼亚大学达顿商学院的MBA学位。
- Catherine J. Friedman has served as a member of our board of directors since September 2020. Ms. Friedman has been an independent financial consultant serving public and private companies in the life sciences industry since 2006. Ms. Friedman served in various executive roles from 1982 to 2006 at Morgan Stanley, an investment bank and financial services company, including as Manager Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. She currently serves as Chairperson of the board at GRAIL, Inc., a cancer testing company, and on the board of directors of Altaba Inc., a closed-end management investment company formerly Yahoo! Inc., and Radius Health, Inc., a biopharmaceutical company. Ms. Friedman previously served on the board of directors of EnteroMedics, Inc., GSV Capital Corp., Innoviva, Inc. (formerly Theravance, Inc.), and XenoPort, Inc. She holds an A.B. in Economics from Harvard University and an M.B.A. from the University of Virginia Darden School of Business, where she serves as a member of the Darden School Foundation Board of Trustees.
- David Singer
-
David Singer，2006年起担任董事会成员。2004年起，他成为私募投资公司Maverick Capital Ltd.的一名管理对冲基金和私募投资基金的注册投资咨询师，负责公司的全球私募投资业务。他2008年成为Maverick Capital Ltd.的合伙人。此前，他是一名企业家，担任包括Affymetrix, Inc.在内的三家医疗护理公司的创始总裁和首席执行官。他现在多家私营公司董事会服务，此前1993至2008年6月担任Affymetrix的董事，1998至2008年6月担任Concept Therapeutics的董事，2004年2月至2006年6月担任Oscient Pharmaceuticals的董事，也在两家上市公司担任高级财务职务。他获有Yale University的学士学位，以及Stanford University的工商管理硕士学位。
David Singer has served as a member of our board of directors since December 2017. Mr. Singer has held various positions at Maverick Ventures, a venture capital firm, or its affiliates, since December 2004 including Managing Partner of Maverick Ventures since February 2015. Mr. Singer currently serves on the board of directors of 1Life Healthcare, Inc. OneMedical, Castlight Health, Inc. and several privately-held companies. Previously, Mr. Singer served on the board of four other public companies, including Pacific BioSciences of California, Inc. and Affymetrix, Inc., where he was the founding CEO. He previously served as a health commissioner of San Francisco and a member of the San Francisco General Hospital Joint Conference Committee from July 2013 to January 2017. He holds a B.A. in History from Yale University and an M.B.A. from Stanford University. - David Singer，2006年起担任董事会成员。2004年起，他成为私募投资公司Maverick Capital Ltd.的一名管理对冲基金和私募投资基金的注册投资咨询师，负责公司的全球私募投资业务。他2008年成为Maverick Capital Ltd.的合伙人。此前，他是一名企业家，担任包括Affymetrix, Inc.在内的三家医疗护理公司的创始总裁和首席执行官。他现在多家私营公司董事会服务，此前1993至2008年6月担任Affymetrix的董事，1998至2008年6月担任Concept Therapeutics的董事，2004年2月至2006年6月担任Oscient Pharmaceuticals的董事，也在两家上市公司担任高级财务职务。他获有Yale University的学士学位，以及Stanford University的工商管理硕士学位。
- David Singer has served as a member of our board of directors since December 2017. Mr. Singer has held various positions at Maverick Ventures, a venture capital firm, or its affiliates, since December 2004 including Managing Partner of Maverick Ventures since February 2015. Mr. Singer currently serves on the board of directors of 1Life Healthcare, Inc. OneMedical, Castlight Health, Inc. and several privately-held companies. Previously, Mr. Singer served on the board of four other public companies, including Pacific BioSciences of California, Inc. and Affymetrix, Inc., where he was the founding CEO. He previously served as a health commissioner of San Francisco and a member of the San Francisco General Hospital Joint Conference Committee from July 2013 to January 2017. He holds a B.A. in History from Yale University and an M.B.A. from Stanford University.
- David Hallal
-
David Hallal， 2006年6月加入Alexion公司，并自2012年10月起出任执行副总裁兼首席商务官。自从加入Alexion公司，曾担任过多个高级商业职位，包括从2006年6月至2008年11月高级副总裁，负责美国商业运营；从2008年11月至2010年5月高级副总裁，负责美洲商业运营；然后从2010年5月至2012年10月高级副总裁，负责全球商业运营。在加入Alexion公司前，从2004年4月至2006年6月，担任OSI Eyetech公司销售副总裁，他带领推出美国第一流的治疗年龄相关性黄斑变性的抗VEGF。在OSI Eyetech之前，自1992年至2004年曾在安进公司和Biogen Idec公司担任各种销售和营销领导职务，在那里他参与了在血液学，肿瘤学，肾脏病学和免疫学领域的多个产品的推出。 他从新罕布什尔大学获得了心理学学士学位。
David Hallal,has served as the Chairman of Scholar Rock Holding Corporation Board of Directors since July 2017. He also serves as the Chairman of the Board of Directors of iTeos Therapeutics SA and as a member of the Board of Directors of Seer Biosciences, Inc. Since December 2017, Mr. Hallal has served as Chairman and Chief Executive Officer of ElevateBio, LLC. From September 2018 until May 2021, Mr. Hallal served as Chairman and Chief Executive Officer of AlloVir, Inc. and since May 2021, serves as its Executive Chairman. Prior to that, from June 2006 to December 2016, Mr. Hallal served in executive roles of increasing responsibility at Alexion Pharmaceuticals, Inc., most recently serving as Chief Executive Officer and a board member. Prior to his role as CEO, Mr. Hallal served Alexion as COO and a board member as well as Chief Commercial Officer and Head of Commercial Operations. Prior to Alexion from 2004 to 2006, Mr. Hallal served as Vice President of Sales for OSI Eyetech, Inc. From 2002 to 2004, Mr. Hallal served as Head of Sales at Biogen Inc. From 1992 to 2002, Mr. Hallal held various leadership roles at Amgen Inc. From 1988 to 1992, Mr. Hallal began his pharmaceutical career at The Upjohn Company as a sales representative. Mr. Hallal holds a B.A. in psychology from the University of New Hampshire. - David Hallal， 2006年6月加入Alexion公司，并自2012年10月起出任执行副总裁兼首席商务官。自从加入Alexion公司，曾担任过多个高级商业职位，包括从2006年6月至2008年11月高级副总裁，负责美国商业运营；从2008年11月至2010年5月高级副总裁，负责美洲商业运营；然后从2010年5月至2012年10月高级副总裁，负责全球商业运营。在加入Alexion公司前，从2004年4月至2006年6月，担任OSI Eyetech公司销售副总裁，他带领推出美国第一流的治疗年龄相关性黄斑变性的抗VEGF。在OSI Eyetech之前，自1992年至2004年曾在安进公司和Biogen Idec公司担任各种销售和营销领导职务，在那里他参与了在血液学，肿瘤学，肾脏病学和免疫学领域的多个产品的推出。 他从新罕布什尔大学获得了心理学学士学位。
- David Hallal,has served as the Chairman of Scholar Rock Holding Corporation Board of Directors since July 2017. He also serves as the Chairman of the Board of Directors of iTeos Therapeutics SA and as a member of the Board of Directors of Seer Biosciences, Inc. Since December 2017, Mr. Hallal has served as Chairman and Chief Executive Officer of ElevateBio, LLC. From September 2018 until May 2021, Mr. Hallal served as Chairman and Chief Executive Officer of AlloVir, Inc. and since May 2021, serves as its Executive Chairman. Prior to that, from June 2006 to December 2016, Mr. Hallal served in executive roles of increasing responsibility at Alexion Pharmaceuticals, Inc., most recently serving as Chief Executive Officer and a board member. Prior to his role as CEO, Mr. Hallal served Alexion as COO and a board member as well as Chief Commercial Officer and Head of Commercial Operations. Prior to Alexion from 2004 to 2006, Mr. Hallal served as Vice President of Sales for OSI Eyetech, Inc. From 2002 to 2004, Mr. Hallal served as Head of Sales at Biogen Inc. From 1992 to 2002, Mr. Hallal held various leadership roles at Amgen Inc. From 1988 to 1992, Mr. Hallal began his pharmaceutical career at The Upjohn Company as a sales representative. Mr. Hallal holds a B.A. in psychology from the University of New Hampshire.
- Robert Langer
-
Robert Langer，自2005年起担任麻省理工学院教授，在此之前，自1977年起担任麻省理工学院教授。从1995年到2002年，他担任美国食品和药物管理局科学委员会成员，包括四年的主席。他是美国国家科学院、美国国家工程院和美国国家医学院的当选成员。
Robert Langer,has been an Institute Professor at the Massachusetts Institute of Technology (MIT) since 2005, and has been a Professor at MIT since 1977. Dr. Langer served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including as chairman for four years. He is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine and the National Academy of Inventors. Dr. Langer has written over 1,550 articles and also has 1,450 issued or pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies. B.S. in chemical engineering from Cornell University .Sc.D. in chemical engineering from the Massachusetts Institute of Technology. - Robert Langer，自2005年起担任麻省理工学院教授，在此之前，自1977年起担任麻省理工学院教授。从1995年到2002年，他担任美国食品和药物管理局科学委员会成员，包括四年的主席。他是美国国家科学院、美国国家工程院和美国国家医学院的当选成员。
- Robert Langer,has been an Institute Professor at the Massachusetts Institute of Technology (MIT) since 2005, and has been a Professor at MIT since 1977. Dr. Langer served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including as chairman for four years. He is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine and the National Academy of Inventors. Dr. Langer has written over 1,550 articles and also has 1,450 issued or pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies. B.S. in chemical engineering from Cornell University .Sc.D. in chemical engineering from the Massachusetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Omid Farokhzad
Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
Omid Farokhzad,has served as a member of Senti Biosciences, Inc. board of directors since the closing of Senti Biosciences, Inc. Business Combination in June 2022. He founded Seer, Inc. (Nasdaq: SEER) in 2017, which advances a transformative proteomics platform, and has served as its Chief Executive Officer since February 2018 and as a member of its board of directors since March 2017, serving as the Chair since September 2020. He also served as Founder, Chief Executive Officer and Chair of Senti Biosciences, Inc. predecessor, Dynamics Special Purpose Corp. (NASDAQ: DYNS) from March 2021 to June 2022. He previously co-founded BIND Therapeutics (acquired by Pfizer Inc. (NYSE: PFE)), Selecta Biosciences, Inc. (Nasdaq: SELB), which is developing a novel antigen-specific tolerance platform for biologics and gene therapy, and Tarveda Therapeutics, Inc., a privately held oncology biotherapeutics company. From September 2004 to February 2018, he was a Professor at Harvard Medical School and a director of the Center for Nanomedicine at Brigham and Women's Hospital. Dr. Farokhzad holds an MA and M.D. from Boston University and an MBA from MIT Sloan School of Management.- Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
- Omid Farokhzad,has served as a member of Senti Biosciences, Inc. board of directors since the closing of Senti Biosciences, Inc. Business Combination in June 2022. He founded Seer, Inc. (Nasdaq: SEER) in 2017, which advances a transformative proteomics platform, and has served as its Chief Executive Officer since February 2018 and as a member of its board of directors since March 2017, serving as the Chair since September 2020. He also served as Founder, Chief Executive Officer and Chair of Senti Biosciences, Inc. predecessor, Dynamics Special Purpose Corp. (NASDAQ: DYNS) from March 2021 to June 2022. He previously co-founded BIND Therapeutics (acquired by Pfizer Inc. (NYSE: PFE)), Selecta Biosciences, Inc. (Nasdaq: SELB), which is developing a novel antigen-specific tolerance platform for biologics and gene therapy, and Tarveda Therapeutics, Inc., a privately held oncology biotherapeutics company. From September 2004 to February 2018, he was a Professor at Harvard Medical School and a director of the Center for Nanomedicine at Brigham and Women's Hospital. Dr. Farokhzad holds an MA and M.D. from Boston University and an MBA from MIT Sloan School of Management.
- Elona Kogan
Elona Kogan自2020年11月起担任我们的总法律顾问兼秘书。在加入我们之前，Kogan女士于2019年3月至2020年8月担任临床阶段生物技术公司SelectaBiosciences，Inc.的总法律顾问兼秘书。2016年7月至2017年4月，高根女士担任罕见疾病肿瘤公司ARIADPharmaceuticals，Inc.的总法律顾问兼政府关系主管，在武田制药有限公司（Takeda Pharmaceuticals Company Limited）收购该公司的过程中，她是该公司的主要高管。Kogan女士于2011年5月至2015年8月领导AvanirPharmaceuticals，Inc.（一家公开上市的制药公司）的法律和政府事务职能，直到其被Otsuka Pharmaceutical Co.Ltd.收购。之前的职位包括在King Pharmaceuticals，Inc.，Bristol-Myers Squibb和Bergen Brunswig Corporation担任越来越重要的职位。Kogan女士也是Cardax，Inc.的董事会成员，并担任薪酬委员会主席和审计委员会成员。Kogan女士毕业于西南大学法学院（Southwestern University School of Law）规模计划。Kogan女士以优异成绩毕业于Columbia University，Barnard College，获得经济学学士学位。
Elona Kogan has served as our General Counsel and Secretary since November 2020. Prior to joining us, Ms. Kogan served as General Counsel and Secretary of Selecta Biosciences, Inc., a clinical-stage biotechnology company, from March 2019 to August 2020. From July 2016 to April 2017 Ms. Kogan served as General Counsel and Head of Government Relations at ARIAD Pharmaceuticals, Inc., a rare disease oncology company, where she was a key executive through the acquisition of the company by Takeda Pharmaceuticals Company Limited. Ms. Kogan led the legal and government affairs functions of Avanir Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from May 2011 to August 2015 until its acquisition by Otsuka Pharmaceutical Co. Ltd. Prior roles included positions of increasing responsibility at King Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bergen Brunswig Corporation. Ms. Kogan is also a member of the board of Cardax, Inc. and serves as the Chairperson of the Compensation Committee and a member of the Audit Committee. Ms. Kogan is a graduate of the SCALE program at Southwestern University School of Law. Ms. Kogan graduated cum laude from Columbia University, Barnard College, with a B.A. in economics.- Elona Kogan自2020年11月起担任我们的总法律顾问兼秘书。在加入我们之前，Kogan女士于2019年3月至2020年8月担任临床阶段生物技术公司SelectaBiosciences，Inc.的总法律顾问兼秘书。2016年7月至2017年4月，高根女士担任罕见疾病肿瘤公司ARIADPharmaceuticals，Inc.的总法律顾问兼政府关系主管，在武田制药有限公司（Takeda Pharmaceuticals Company Limited）收购该公司的过程中，她是该公司的主要高管。Kogan女士于2011年5月至2015年8月领导AvanirPharmaceuticals，Inc.（一家公开上市的制药公司）的法律和政府事务职能，直到其被Otsuka Pharmaceutical Co.Ltd.收购。之前的职位包括在King Pharmaceuticals，Inc.，Bristol-Myers Squibb和Bergen Brunswig Corporation担任越来越重要的职位。Kogan女士也是Cardax，Inc.的董事会成员，并担任薪酬委员会主席和审计委员会成员。Kogan女士毕业于西南大学法学院（Southwestern University School of Law）规模计划。Kogan女士以优异成绩毕业于Columbia University，Barnard College，获得经济学学士学位。
- Elona Kogan has served as our General Counsel and Secretary since November 2020. Prior to joining us, Ms. Kogan served as General Counsel and Secretary of Selecta Biosciences, Inc., a clinical-stage biotechnology company, from March 2019 to August 2020. From July 2016 to April 2017 Ms. Kogan served as General Counsel and Head of Government Relations at ARIAD Pharmaceuticals, Inc., a rare disease oncology company, where she was a key executive through the acquisition of the company by Takeda Pharmaceuticals Company Limited. Ms. Kogan led the legal and government affairs functions of Avanir Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from May 2011 to August 2015 until its acquisition by Otsuka Pharmaceutical Co. Ltd. Prior roles included positions of increasing responsibility at King Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bergen Brunswig Corporation. Ms. Kogan is also a member of the board of Cardax, Inc. and serves as the Chairperson of the Compensation Committee and a member of the Audit Committee. Ms. Kogan is a graduate of the SCALE program at Southwestern University School of Law. Ms. Kogan graduated cum laude from Columbia University, Barnard College, with a B.A. in economics.
- David R. Horn
David R.Horn自2020年5月起担任我们的首席财务官。在加入我们之前，霍恩先生于2007年5月至2020年5月在投资银行和金融服务公司摩根士丹利任职，在那里他曾担任投资银行部全球梦百合集团的董事总经理。从2003年5月到2007年5月，Horn先生担任Montgomery&Co.，LLC的负责人，这是一家并购与私募服务提供商。他持有Princeton University的政治学士学位，以及Stanford University Graduate School of Business的工商管理硕士学位。
David R. Horn has served as our Chief Financial Officer since May 2020. Prior to joining us, Mr. Horn was with Morgan Stanley, an investment bank and financial services company, from May 2007 to May 2020 where he served as a Managing Director in the Global Healthcare Group within the Investment Banking Department. From May 2003 to May 2007 Mr. Horn served as a Principal at Montgomery & Co., LLC, a provider of merger and acquisition and private placement services. He holds an A.B. in Politics from Princeton University and an M.B.A. from Stanford University Graduate School of Business.- David R.Horn自2020年5月起担任我们的首席财务官。在加入我们之前，霍恩先生于2007年5月至2020年5月在投资银行和金融服务公司摩根士丹利任职，在那里他曾担任投资银行部全球梦百合集团的董事总经理。从2003年5月到2007年5月，Horn先生担任Montgomery&Co.，LLC的负责人，这是一家并购与私募服务提供商。他持有Princeton University的政治学士学位，以及Stanford University Graduate School of Business的工商管理硕士学位。
- David R. Horn has served as our Chief Financial Officer since May 2020. Prior to joining us, Mr. Horn was with Morgan Stanley, an investment bank and financial services company, from May 2007 to May 2020 where he served as a Managing Director in the Global Healthcare Group within the Investment Banking Department. From May 2003 to May 2007 Mr. Horn served as a Principal at Montgomery & Co., LLC, a provider of merger and acquisition and private placement services. He holds an A.B. in Politics from Princeton University and an M.B.A. from Stanford University Graduate School of Business.
- Omead Ostadan
Omead Ostadan自2020年7月起担任Seer，Inc.的总裁兼首席运营官，并自2020年3月起成为Seer，Inc.的董事会成员。在加入Seer，Inc.之前，Ostadan先生于2007年1月至2020年6月在生物技术公司Illumina，Inc.任职，担任各种执行职务，最近于2019年7月至2020年6月担任高级副总裁兼首席产品和营销官，2015年4月至2019年6月任产品和营销高级副总裁。奥斯塔丹先生拥有加利福尼亚大学戴维斯分校生物化学理学学士学位和沃顿商学院工商管理硕士学位。
Omead Ostadan has served as Seer, Inc.'s President and Chief Operating Officer since July 2020 and as a member of Seer, Inc.'s board of directors since March 2020. Prior to joining Seer, Inc., Mr. Ostadan was with Illumina, Inc., a biotechnology company, from January 2007 to June 2020 where he served in various executive roles, most recently as Senior Vice President & Chief Products and Marketing Officer from July 2019 to June 2020 and Senior Vice President, Products & Marketing from April 2015 to June 2019. Mr. Ostadan holds a B.Sc in Biochemistry from the University of California, Davis and an M.B.A from the Wharton School of Business.- Omead Ostadan自2020年7月起担任Seer，Inc.的总裁兼首席运营官，并自2020年3月起成为Seer，Inc.的董事会成员。在加入Seer，Inc.之前，Ostadan先生于2007年1月至2020年6月在生物技术公司Illumina，Inc.任职，担任各种执行职务，最近于2019年7月至2020年6月担任高级副总裁兼首席产品和营销官，2015年4月至2019年6月任产品和营销高级副总裁。奥斯塔丹先生拥有加利福尼亚大学戴维斯分校生物化学理学学士学位和沃顿商学院工商管理硕士学位。
- Omead Ostadan has served as Seer, Inc.'s President and Chief Operating Officer since July 2020 and as a member of Seer, Inc.'s board of directors since March 2020. Prior to joining Seer, Inc., Mr. Ostadan was with Illumina, Inc., a biotechnology company, from January 2007 to June 2020 where he served in various executive roles, most recently as Senior Vice President & Chief Products and Marketing Officer from July 2019 to June 2020 and Senior Vice President, Products & Marketing from April 2015 to June 2019. Mr. Ostadan holds a B.Sc in Biochemistry from the University of California, Davis and an M.B.A from the Wharton School of Business.
- Elona Kogan
Elona Kogan，自2020年11月起担任Avanir Pharmaceuticals, Inc.的总法律顾问兼秘书。Kogan女士于2011年5月加入Avanir担任法律事务部副总裁。Kogan女士负责管理Avanir的法律事务，并为董事会主席和首席执行官与董事提供法律顾问服务。加入Avanir前，Kogan女士担任君王制药公司（King Pharmaceuticals, Inc.）的副总法律顾问与隐私官，这是一家上市的制药公司。除了为首席商务官提供法律顾问服务，并协助制定公司商业战略外，Kogan女士担任多个法律事务职务，包括合规、病患辅导计划、隐私事务、合同签订诉讼与公司治理。加入King Pharmaceuticals, Inc.前，Kogan女士在百时美施贵宝公司（Bristol-Myers Squibb）、Bergen Brunswick与爱宾格林律师事务所（Epstein, Becker & Green）任职。Kogan女士在哥伦比亚大学（Columbia University）以优异成绩获得经济学学士学位，并在美国西南大学（Southwestern University）法学院获得法学博士学位。
Elona Kogan. Ms. Kogan joined Avanir in the role of Vice President of the Legal Affairs Department in May 2011. Ms. Kogan is responsible for Avanir's legal affairs, as well as providing counsel to the chairman and chief executive officer and its Board of Directors. Prior to joining Avanir, Ms. Kogan was Associate General Counsel and Privacy Officer at King Pharmaceuticals, Inc., a publicly traded pharmaceutical company. In addition to providing counsel to the chief commercial officer, and helping shape company commercial strategy, Ms. Kogan worked on a variety of legal issues, including, regulatory compliance, patient assistance programs, privacy issues, contracting, litigation and corporate governance. Prior to joining King Pharmaceuticals, Ms. Kogan worked at Bristol-Myers Squibb, Bergen Brunswick, and Epstein, Becker & Green. Ms. Kogan earned a B.A. degree, cum laude from Columbia University, and a Juris Doctor degree from the Southwestern University School of Law.- Elona Kogan，自2020年11月起担任Avanir Pharmaceuticals, Inc.的总法律顾问兼秘书。Kogan女士于2011年5月加入Avanir担任法律事务部副总裁。Kogan女士负责管理Avanir的法律事务，并为董事会主席和首席执行官与董事提供法律顾问服务。加入Avanir前，Kogan女士担任君王制药公司（King Pharmaceuticals, Inc.）的副总法律顾问与隐私官，这是一家上市的制药公司。除了为首席商务官提供法律顾问服务，并协助制定公司商业战略外，Kogan女士担任多个法律事务职务，包括合规、病患辅导计划、隐私事务、合同签订诉讼与公司治理。加入King Pharmaceuticals, Inc.前，Kogan女士在百时美施贵宝公司（Bristol-Myers Squibb）、Bergen Brunswick与爱宾格林律师事务所（Epstein, Becker & Green）任职。Kogan女士在哥伦比亚大学（Columbia University）以优异成绩获得经济学学士学位，并在美国西南大学（Southwestern University）法学院获得法学博士学位。
- Elona Kogan. Ms. Kogan joined Avanir in the role of Vice President of the Legal Affairs Department in May 2011. Ms. Kogan is responsible for Avanir's legal affairs, as well as providing counsel to the chairman and chief executive officer and its Board of Directors. Prior to joining Avanir, Ms. Kogan was Associate General Counsel and Privacy Officer at King Pharmaceuticals, Inc., a publicly traded pharmaceutical company. In addition to providing counsel to the chief commercial officer, and helping shape company commercial strategy, Ms. Kogan worked on a variety of legal issues, including, regulatory compliance, patient assistance programs, privacy issues, contracting, litigation and corporate governance. Prior to joining King Pharmaceuticals, Ms. Kogan worked at Bristol-Myers Squibb, Bergen Brunswick, and Epstein, Becker & Green. Ms. Kogan earned a B.A. degree, cum laude from Columbia University, and a Juris Doctor degree from the Southwestern University School of Law.